Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease.
SFB 1399
Mechanisms of Drug Sensitivity
and Resistance in Small Cell Lung Cancer
c/o Department of Translational Genomics
University of Cologne
Weyertal 115b
50931 Cologne, Germany
Partners:
